Skip to main content
. 2022 Apr 21;65(7):1085–1097. doi: 10.1007/s00125-022-05694-6

Fig. 5.

Fig. 5

Effect of dapagliflozin on the primary composite outcome across baseline UACR levels in patients with diabetes (a) and without diabetes (b). The solid line indicates the HR for the primary outcome across baseline UACR, on the left y-axis plotted on a natural log scale; the shaded area indicates the 95% CI. The histogram shows the distribution of UACR at baseline, by number of participants on the right y-axis